Table 3. Mutational status and allelic... | American Society of Hematology

Table 3.

Mutational status and allelic frequency at screening and before initiating cycle 3 of treatment

Patient ID	Screening		Cycle 3
Patient ID	Abnormal allele	Allelic frequency (%)	Abnormal allele	Allelic frequency (%)
101	MPL*	91	MPL*	93.6
	PHF6*	40	PHF6*	43.6
	TET2*	46	TET2*	47
	KRAS*	40	KRAS*	37.8
	ASXL1**	39	ASXL1**	12.5
102	JAK2	41.4	JAK2	46.8
103	CALR**	11.7	CALR**	10.3
	ASXL1**	19.2	ASXL1**	13.7
	KMT2D**	37.7	KMT2D**	36.7
	KLF2*	42.6	KLF2*	48.6
104	JAK2*	51.1	JAK2*	45.2
	SF3B1*	41.9	SF3B1*	31.9
	CEBBP*	50.9	CEBBP*	48
105	JAK2*	76.7	JAK2*	77.2
	SF3B1*	48.1	SF3B1*	50.7
	EZH2*	3.1	EZH2*	3.4
	ATM*	36.9	ATM*	39.9
	IKZF1*	19	IKZF1*	29.1
106	JAK2*		JAK2*	5.6
	SETBP1*	6.3	SETBP1*	39.4
	NRAS*	31.3/19.8/45	NRAS*	35.7
	PHF6*	9.9	PHF6*	11.8
	RUNX1*	17.3	RUNX1*	21.5
	EZH2*	31.9	EZH2*	18.9
	X	X	CCND2*	11.2
109	MPL*	15.8	MPL*	12
	IDH2*	50.6	IDH2*	53.5
	SRSF2*	45.2	SRSF2*	49.2
	SH2B3**	71.1	SH2B3**	74.9
111	JAK2*	49.7	JAK2**	59.5
	PRPF40B*	42.6	PRPF40B*	43.2

Patient ID	Screening		Cycle 3
Patient ID	Abnormal allele	Allelic frequency (%)	Abnormal allele	Allelic frequency (%)
101	MPL*	91	MPL*	93.6
	PHF6*	40	PHF6*	43.6
	TET2*	46	TET2*	47
	KRAS*	40	KRAS*	37.8
	ASXL1**	39	ASXL1**	12.5
102	JAK2	41.4	JAK2	46.8
103	CALR**	11.7	CALR**	10.3
	ASXL1**	19.2	ASXL1**	13.7
	KMT2D**	37.7	KMT2D**	36.7
	KLF2*	42.6	KLF2*	48.6
104	JAK2*	51.1	JAK2*	45.2
	SF3B1*	41.9	SF3B1*	31.9
	CEBBP*	50.9	CEBBP*	48
105	JAK2*	76.7	JAK2*	77.2
	SF3B1*	48.1	SF3B1*	50.7
	EZH2*	3.1	EZH2*	3.4
	ATM*	36.9	ATM*	39.9
	IKZF1*	19	IKZF1*	29.1
106	JAK2*		JAK2*	5.6
	SETBP1*	6.3	SETBP1*	39.4
	NRAS*	31.3/19.8/45	NRAS*	35.7
	PHF6*	9.9	PHF6*	11.8
	RUNX1*	17.3	RUNX1*	21.5
	EZH2*	31.9	EZH2*	18.9
	X	X	CCND2*	11.2
109	MPL*	15.8	MPL*	12
	IDH2*	50.6	IDH2*	53.5
	SRSF2*	45.2	SRSF2*	49.2
	SH2B3**	71.1	SH2B3**	74.9
111	JAK2*	49.7	JAK2**	59.5
	PRPF40B*	42.6	PRPF40B*	43.2

(*) Single nucleotide variant; (**) insertion/deletion.